Literature DB >> 23890874

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

Kenneth E Rosenzweig1, Joe Yujiao Chang, Indrin J Chetty, Roy H Decker, Mark E Ginsburg, Larry L Kestin, Feng-Ming Spring Kong, Brian E Lally, Corey J Langer, Benjamin Movsas, Gregory M M Videtic, Henning Willers.   

Abstract

Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG(®) reported >97% local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Copyright © 2013 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Appropriateness criteria; non–small-cell lung cancer; palliation; radiation therapy

Mesh:

Year:  2013        PMID: 23890874     DOI: 10.1016/j.jacr.2013.05.031

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  5 in total

1.  Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer.

Authors:  Matthew Koshy; Renuka Malik; Usama Mahmood; Zain Husain; Ralph R Weichselbaum; David J Sher
Journal:  J Natl Cancer Inst       Date:  2015-09-30       Impact factor: 13.506

2.  Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.

Authors:  Hui Luo; Hong Ge; Yingying Cui; Jiangong Zhang; Ruitai Fan; Anping Zheng; Xiaoli Zheng; Yanan Sun
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

3.  Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer.

Authors:  Daniel W Kim; Grace Lee; Hwan Lee; Jack M Qian; Nina N Sanford; Miranda B Lam; Naeem Tahir; Harvey J Mamon
Journal:  Adv Radiat Oncol       Date:  2019-12-31

4.  Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non-small-cell lung cancer.

Authors:  Zhibo Tan; Chuanyao Liu; Ying Zhou; Weixi Shen
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

5.  Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Authors:  Pierpaolo Pastina; Valerio Nardone; Cirino Botta; Stefania Croci; Paolo Tini; Giuseppe Battaglia; Veronica Ricci; Maria Grazia Cusi; Claudia Gandolfo; Gabriella Misso; Silvia Zappavigna; Michele Caraglia; Antonio Giordano; Donatella Aldinucci; Pierfrancesco Tassone; Pierosandro Tagliaferri; Luigi Pirtoli; Pierpaolo Correale
Journal:  Oncotarget       Date:  2017-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.